What is Neurocrine Biosciences's license — deferred revenue recognized?

Neurocrine Biosciences (NBIX) reported license — deferred revenue recognized of $1.30M in Q2 2021.

What does license — deferred revenue recognized mean?

The amount of previously collected licensing fees that has been officially recorded as revenue during the current period.

Discontinued — last reported Q2 '21

Products & Services · Deferred revenue recognized

License — Deferred revenue recognized

Analysis

StatementSegment

CategoryProfitability

SignalHigher is better

VolatilityStable

First reportedQ2 2021

Last reportedQ2 2021Aug 3, 2021

Rolls up toContract With Customer Liability Revenue Recognized

How to read this metric

An increase indicates that the company is successfully meeting its contractual obligations and moving closer to completing its performance requirements under partnership agreements.

Detailed definition

This metric reflects the portion of previously deferred licensing revenue that has been moved to the income statement du...

Peer comparison

Standard accounting practice for revenue recognition under ASC 606 or IFRS 15 for companies with multi-year licensing or service contracts.

Metric ID: nbix_segment_license_deferred_revenue_recognized

Historical Data

1 periods

	Q2 '21
Value	$1.30M

Similar Metrics at Other Companies

BiogenBIIB View metric

Natera, Inc.NTRA View metric

Estee Lauder Companies Inc.EL View metric

Rivian Automotive, Inc.RIVN View metric

Estee Lauder Companies Inc.EL View metric

ModernaMRNA View metric

Frequently Asked Questions

What is Neurocrine Biosciences's license — deferred revenue recognized?: Neurocrine Biosciences (NBIX) reported license — deferred revenue recognized of $1.30M in Q2 2021.
What does license — deferred revenue recognized mean?: The amount of previously collected licensing fees that has been officially recorded as revenue during the current period.